Blueprint Medicines (Blueprint Medicines) Cash-to-Debt : 1.96 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Blueprint Medicines's cash to debt ratio for the quarter that ended in Mar. 2024 was 1.96.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Blueprint Medicines could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Blueprint Medicines's Cash-to-Debt or its related term are showing as below:

BPMC' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.96 Med: 8.11 Max: 56.97
Current: 1.96

During the past 11 years, Blueprint Medicines's highest Cash to Debt Ratio was 56.97. The lowest was 1.96. And the median was 8.11.

BPMC's Cash-to-Debt is ranked worse than
68.14% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs BPMC: 1.96

Blueprint Medicines Cash-to-Debt Historical Data

The historical data trend for Blueprint Medicines's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Blueprint Medicines Cash-to-Debt Chart

Blueprint Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

5.04

9.73

4.28

3.90

2.14

Blueprint Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															3.42	3.03	2.13	2.14	1.96

Competitive Comparison of Blueprint Medicines's Cash-to-Debt

For the Biotechnology subindustry, Blueprint Medicines's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blueprint Medicines's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Cash-to-Debt falls into.

Blueprint Medicines Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Blueprint Medicines's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	710.641	/	(42.211	+	290.286)
	=	2.14

Blueprint Medicines's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	647.901	/	(42.42	+	287.694)
	=	1.96

Blueprint Medicines (NAS:BPMC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Blueprint Medicines Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines (Blueprint Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (NAS:BPMC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

2L9:Germany 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Executives

Ariel Hurley	officer: Principal Accounting Officer	C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey W. Albers	director, officer: CEO & President	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Christopher K. Murray	officer: SVP, Technical Operations	C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Fouad Namouni	officer: President, R and D	535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116
L. Becker Hewes	officer: Chief Medical Officer	C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139
Percy H. Carter	officer: Chief Scientific Officer	C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Philina Lee	officer: Chief Commercial Officer	C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Christina Rossi	officer: Chief Commercial Officer	45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139
Tracey L Mccain	officer: EVP and Chief Legal Officer	C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Michael Landsittel	officer: Principal FAO	BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Debra Durso-bumpus	officer: Chief People Officer	C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Kate Haviland	officer: Chief Business Officer	BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
John Tsai	director	BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
George Demetri	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142